[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES

4 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TEST TYPE
5.1 OVERVIEW
5.2 CLINICAL CHEMISTRY
5.3 MOLECULAR DIAGNOSTICS
5.4 IMMUNO-DIAGNOSTICS
5.5 HAEMATOLOGY
5.6 OTHER TEST TYPES

6 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 INSTRUMENTS
6.3 REAGENTS
6.4 OTHER PRODUCTS

7 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY USABILITY
7.1 OVERVIEW
7.2 DISPOSABLE IVD DEVICES
7.3 REUSABLE IVD DEVICES 

8 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 INFECTIOUS DISEASES
8.3 DIABETES
8.4 CANCER/ONCOLOGY
8.5 CARDIOLOGY
8.6 AUTOIMMUNE DISEASES
8.7 NEPHROLOGY
8.8 OTHER APPLICATIONS

9 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END-USER
9.1 OVERVIEW
9.2 DIAGNOSTIC LABORATORIES
9.3 HOSPITALS AND CLINICS
9.4 OTHER END USERS 

10 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY
10.1 OVERVIEW
10.2 INDIA
10.3 JAPAN
10.4 SOUTH KOREA
10.5 AUSTRALIA & NEW ZEALAND
10.6 ASEAN
10.7 REST OF ASIA PACIFIC

11 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPANY MARKET RANKING
11.3 KEY DEVELOPMENT STRATEGIES

12 COMPANY PROFILES

12.1 BIOMÉRIEUX SA
12.1.1 OVERVIEW
12.1.2 FINANCIAL PERFORMANCE
12.1.3 PRODUCT OUTLOOK
12.1.4 KEY DEVELOPMENTS

12.2 DANAHER (BECKMAN COULTER)
12.2.1 OVERVIEW
12.2.2 FINANCIAL PERFORMANCE
12.2.3 PRODUCT OUTLOOK
12.2.4 KEY DEVELOPMENTS

12.3 F HOFFMANN-LA ROCHE LTD.
12.3.1 OVERVIEW
12.3.2 FINANCIAL PERFORMANCE
12.3.3 PRODUCT OUTLOOK
12.3.4 KEY DEVELOPMENTS

12.4 BECTON, DICKINSON, AND COMPANY
12.4.1 OVERVIEW
12.4.2 FINANCIAL PERFORMANCE
12.4.3 PRODUCT OUTLOOK
12.4.4 KEY DEVELOPMENTS

12.5 BIO-RAD LABORATORIES INC.
12.5.1 OVERVIEW
12.5.2 FINANCIAL PERFORMANCE
12.5.3 PRODUCT OUTLOOK
12.5.4 KEY DEVELOPMENTS

12.6 ABBOTT LABORATORIES
12.6.1 OVERVIEW
12.6.2 FINANCIAL PERFORMANCE
12.6.3 PRODUCT OUTLOOK
12.6.4 KEY DEVELOPMENTS

12.7 ARKRAY INC.
12.7.1 OVERVIEW
12.7.2 FINANCIAL PERFORMANCE
12.7.3 PRODUCT OUTLOOK
12.7.4 KEY DEVELOPMENTS

12.8. SYSMEX CORPORATION
12.8.1 OVERVIEW
12.8.2 FINANCIAL PERFORMANCE
12.8.3 PRODUCT OUTLOOK
12.8.4 KEY DEVELOPMENTS

12.9 ORTHO CLINICAL DIAGNOSTICS
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS

12.10 SIEMENS HEALTHINEERS
12.10.1 OVERVIEW
12.10.2 FINANCIAL PERFORMANCE
12.10.3 PRODUCT OUTLOOK
12.10.4 KEY DEVELOPMENTS

12.11 THERMO FISCHER SCIENTIFIC INC.
12.11.1 OVERVIEW
12.11.2 FINANCIAL PERFORMANCE
12.11.3 PRODUCT OUTLOOK
12.11.4 KEY DEVELOPMENTS

12.12 QIAGEN NV
12.12.1 OVERVIEW
12.12.2 FINANCIAL PERFORMANCE
12.12.3 PRODUCT OUTLOOK
12.12.4 KEY DEVELOPMENTS